Cabaletta Bio
Cabaletta Bio Inc is an American clinical-stage biopharmaceutical company focused on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company utilizes its proprietary Chimeric Autoantibody Receptor T cell (CAART) platform to design targeted cellular therapies that selectively bind and eliminate disease-causing B cells, addressing severe autoimmune conditions such as pemphigus vulgaris, systemic lupus erythematosus, and myositis. Its core operations encompass cellular immunotherapy research, genetic engineering, and clinical trial advancement. As a clinical-stage biotechnology firm, the company generates minimal commercial revenue and finances its research through public equity offerings and pharmaceutical collaborations. Cabaletta Bio holds a pioneering position in targeted cellular immunotherapy for autoimmune diseases. The company is headquartered in Philadelphia, Pennsylvania, United States, and its common stock trades on the Nasdaq Global Select Market.
2 of the funds FundTelligence covers report a position in Cabaletta Bio.
- Legal name
- Cabaletta Bio Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 2
Funds holding Cabaletta Bio
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 0.14 % (full portfolio disclosed, September 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.01 % (full portfolio disclosed, October 2026)